Republic of MoldovaTuberculosis profile
Population  2015 4.1 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.31 (0.3–0.33) 7.7 (7.3–8.1)
Mortality (HIV+TB only) 0.18 (0.11–0.27) 4.5 (2.8–6.6)
Incidence  (includes HIV+TB) 6.2 (4–8.8) 152 (98–217)
Incidence (HIV+TB only) 0.55 (0.35–0.79) 13 (8.5–19)
Incidence (MDR/RR-TB)** 3.9 (2.9–4.8) 96 (71–118)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.17 (0.079–0.27) 1.5 (0.28–2.8) 1.7 (0.36–3.1)
Males 0.17 (0.1–0.25) 4.3 (3–5.6) 4.5 (3.1–5.8)
Total 0.35 (0.23–0.47) 5.8 (4.6–7.1) 6.2 (4–8.8)
TB case notifications, 2015  
Total cases notified 4 211
Total new and relapse 3 608
          - % tested with rapid diagnostics at time of diagnosis 85%
          - % with known HIV status 95%
          - % pulmonary 90%
          - % bacteriologically confirmed among pulmonary 64%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 58% (41–90)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.08 (0.05–0.13)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 300 9%
          - on antiretroviral therapy 197 66%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 700
(1 600–1 800)
Estimated % of TB cases with MDR/RR-TB 32% (29–34) 69% (66–72)  
% notified tested for rifampicin resistance 56% 58% 2 390
MDR/RR-TB cases tested for resistance to second-line drugs   480
Laboratory-confirmed cases MDR/RR-TB: 1 042, XDR-TB: 55
Patients started on treatment **** MDR/RR-TB: 1 020, XDR-TB: 48
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 79% 3 459
Previously treated cases, excluding relapse, registered in 2014 47% 292
HIV-positive TB cases, all types, registered in 2014 53% 241
MDR/RR-TB cases started on second-line treatment in 2013 57% 943
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 0%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data